Work

Preclinical testing supports combined BET and BRAF inhibition as a promising therapeutic strategy for melanoma.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.9072

Authors: Luca Paoluzzi, Douglas Hanniford, Elena Sokolova, Igor Dolgalev, Adriana Heguy, Iman Osman, Farbod Darvishian, Jinhua Wang, James E. Bradner, Eva Hernando

Institutions: NYU Langone Health, New York University, Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2907958539

Cites:

Cited by: 2

Related to: 10